Charco Neurotech, Ltd.

  • CEO & Founder:
    JUNG, Soo Min



Bringing smiles back to the lives of Parkinson's Disease Patients

Charco Neurotech (Charco) is a developer of a non-invasive wearable medical device “CUE” for the treatment of Parkinson’s Disease (PD) based in Cambridge, United Kingdom. The company was founded in June of 2019 and consists of a team of Oxbridge and Imperial College graduates led by multi award-winning CEO Lucy Jung.
Charco aims to develop and commercialize the “CUE” device which delivers a combination of the medically proven methods of cueing and focused vibrotactile stimulation for the treatment of PD. The company is now planning multiple clinical trials, and the “CUE” is expected to render improvements in various PD symptoms, especially in drug resistant Freezing of Gait (FoG) which is known to be one of the most debilitating symptoms of PD.
The incidence of PD is increasing in Japan where the nation faces an aging population. UTEC will support Charco's market entry and expansion in Japan as a part of the AUGMENT (Amadeus UTEC Global Market Expansion of Novel Technologies) Partnership with Amadeus Capital Partners, which supports the Japan to Europe and Europe to Japan expansion of deep tech start-ups.



Multi-award winning entrepreneur Lucy Jung realized the potential of stimulatory treatments when she designed the "Arc Pen“ which proved effective on patients with microphilia. Believing in the potential of a non-invasive device that would treat Parkinson's Disease through the proven mechanisms of cueing and focused vibrotactile stimulation, Lucy founded the company in June 2019.


Unprecedented product "CUE" that combines focused vibrotactile stimulation and cueing for the non-invasive treatment of Parkinson's Disease.

UTEC’s value add

Hands-on support in regulatory approval and commercial expansion of the Charco Neurotech "CUE" device in Japan, where an aging population is causing a significant increase in the incidence of Parkinson's Disease.
  • The Charco "CUE" Device

  • PD patient with the packaged CUE Device